METHODS: This analysis is part of a cross-sectional, matched-cohort study. We recruited two groups of women with episodic migraine: one with a regular menstrual cycle (M-RMC) and another undergoing combined oral contraceptive treatment (M-COC). Additionally, we included corresponding age-matched control groups without migraine for both categories (C-RMC and C-COC). For participants with a RMC, the study visits were scheduled during the perimenstrual period (menstrual cycle day 2 ± 2) and periovulatory period (day 13 ± 2). Participants using COC were examined at day 4 ± 2 of the hormone-free interval and between day 7-14 of the hormone intake phase. During these visits, PACAP-38 concentrations in plasma were measured using a commercial Enzyme-linked-immunosorbent assay (ELISA) kit.
RESULTS: The study included 120 women, with 30 participants in each group. Women with migraine and a RMC had significantly higher PACAP-38 plasma concentrations compared to healthy controls at both study visits [day 2 ± 2: M-RMC: 2547.41 pg/ml (IQR 814.27 - 4473.48) vs. C-RMC: 1129.49 pg/ml (IQR 257.34 - 2684.88), p = 0.025; day 13 ± 2: M-RMC: 3098.89 pg/ml (IQR 1186.29 - 4379.47) vs. C-RMC: 1626.89 (IQR 383.83 - 3038.36), p = 0.028]. In contrast, PACAP-38 levels were comparable between migraine and control groups receiving COC. Women with migraine and a RMC exhibited higher PACAP-38 concentrations during menstruation compared to those using COC during the hormone-free interval.
CONCLUSIONS: Systemic PACAP-38 concentrations in women vary based on the presence of migraine diagnosis and their hormonal status.
方法:此分析是横截面的一部分,配对队列研究。我们招募了两组患有偶发性偏头痛的女性:一组具有规律的月经周期(M-RMC),另一组接受联合口服避孕药治疗(M-COC)。此外,我们纳入了两个类别(C-RMC和C-COC)均无偏头痛的相应年龄匹配对照组.对于有RMC的参与者,研究访视时间安排在围月经期(月经周期第2±2天)和围排卵期(第13±2天)。使用COC的参与者在无激素间隔的第4±2天以及激素摄入阶段的第7-14天之间进行检查。在这些访问期间,使用商业酶联免疫吸附测定(ELISA)试剂盒测量血浆中的PACAP-38浓度。
结果:该研究包括120名女性,每组30人。在两次研究访问中,与健康对照组相比,患有偏头痛和RMC的妇女的PACAP-38血浆浓度明显更高[第2天±2:M-RMC:2547.41pg/ml(IQR814.27-4473.48)与C-RMC:1129.49pg/ml(IQR257.34-2684.88),p=0.025;第13±2天:M-RMC:3098.89pg/ml(IQR1186.29-4379.47)与C-RMC:1626.89(IQR383.83-3038.36),p=0.028]。相比之下,接受COC的偏头痛组和对照组之间的PACAP-38水平相当。与无激素间隔期间使用COC的女性相比,患有偏头痛和RMC的女性在月经期间表现出更高的PACAP-38浓度。
结论:女性的全身PACAP-38浓度因偏头痛的诊断和激素状态而异。